FIELD: medicine; pharmacology.
SUBSTANCE: group of inventions relates to the field of medicine and pharmacology, specifically to methods for treating solid cancers that use a combination of trifluridine/tipiracil hydrochloride medications in combination with irinotecan hydrochloride hydrate. Disclosed is a novel combination therapy for the treatment of solid cancers, including the repetition of one cycle of the regimen of administering to a patient with solid cancer one or two or more times, where for a period of 14 days the combined drug containing trifluridine and tipiracil hydrochloride in a molar ratio of 1:0.5 is administered at a dose of 20 to 80 mg/m2/day, using a reduced amount of trifluridine on days 1 to 5, and irinotecan hydrochloride hydrate is administered at a dose of 50 to 200 mg/m2/day on day 1.
EFFECT: group of inventions provides a synergistic effect of the combination of FTD/TPI and CPT-11 for effective treatment of solid cancers.
15 cl, 5 dwg, 2 tbl, 2 ex
